MedTrace Logo

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

NCT05893797 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-11-10

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.

Conditions

Interventions

DRUG

Insulin Lispro

As prescribed.

DEVICE

Tempo Smart Button

Attached to the Tempo Pen

DEVICE

Dexcom G6 CGM

Continuous glucose monitor

DEVICE

Glooko Research Mobile App (RMA)

Installed on a study provided android phone.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2024-09-16
Completion
2024-09-16
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893797 on ClinicalTrials.gov